RSS

Orchard Therapeutics

Commercial-stage company — Orchard Therapeutics — has completed its Series C financing round, raising $150 million to be used in the advancement of its gene therapy pipeline. Read more

News

Orchard Therapeutics, a commercial stage company, has been granted a Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for its gene therapy candidate, OTL-200, for the treatment of patients with MLD Read more

News

Orchard Therapeutics, a commercial and clinical-stage company, has opened a new US office located in Boston’s Seaport District, building upon the company’s footprint in London as well as Foster City and Menlo Park, California. Read more

News

A strategic agreement has been signed by GlaxoSmithKline (GSK) and Orchard Therapeutics, involving the transfer of GSK’s portfolio of approved and investigational rare disease gene therapies to Orchard. Read more

News

Clinical-stage biotechnology company, Orchard Therapeutics, has opened a second facility in San Francisco, California, expanding its technical operations. Read more

News

Orchard Therapeutics, a clinical-stage biotechnology company, has acquired an exclusive licence to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B (or MPS-IIIB) from The University of Manchester. Read more

News